AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03888339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified shape abutments
Description: Patients will be randomly selected for the modified shape abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, modified high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
Study NCT02606279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
Study NCT02606279 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02256670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Application
Description: Two-way text messaging application addressing adherence with adjuvant endocrine therapy
Study NCT00238030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-thryoxine
Description: 2 mcg/kg iv or 2 mcg/kg po at time of enrollment
Study NCT00238030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv thryoxine
Description: thyroxine 2 mcg/kg iv
Study NCT02860481 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample for FSHR analysis
Study NCT01871779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treadmill Exercise
Description: Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks
Study NCT01871779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent treadmill & resistance training
Description: Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks
Study NCT01037855 — intervention group
Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study
Study NCT01592903 — intervention group
Intervention type: GENETIC
Intervention: Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.
Description: * Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.~* Sample digestion through controlled enzymes.~* Isolated the Side Population from leiomyoma cell suspension by Flow cytometry .~* Culture of these cells.~* Morphological and genetic characterization.~* Assessment of pluripotent potential from isolated cells.~* Analysis of the degree of functionality.
Study NCT04088201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose measurements
Description: We will not conduct an intervention, but will obtain measurements from a continuous, non-invasive glucose sensor, and compare with those from a glucometer.
Study NCT04340310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Home respiratory polygraphy
Description: Home respiratory polygraphy or Polysomnography to stablish a therapeutic decission
Study NCT05961852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty
Description: Angioplasty with cutting and drug-coated balloon
Study NCT03791164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Pain Toolkit
Description: the Pain Toolkit is a leaflet that encourages self management techniques for patients with chronic pain
Study NCT03791164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: the Back Book
Description: The Back Book is a patient information leaflet that offers information and advice about back pain
Study NCT03791164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Back Book
Description: The Back Book is a patient information leaflet that offers information and advice about back pain
Study NCT02138045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
Study NCT02138045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide treatment
Description: Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
Study NCT05308550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: rapid RT-LAMP test to detect SARS-COV-2 RNA
Description: rapid RT-LAMP test to detect SARS-COV-2 RNA
Study NCT01011465 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Social Support
Description: Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
Study NCT01011465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Social Support
Description: Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
Study NCT03190551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retroclavicular approach
Description: Retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
Study NCT03190551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: costoclavicular approach
Description: costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
Study NCT01518855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat, BAYA1040)
Study NCT01518855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine (Norvasc)
Study NCT01518855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diovan
Study NCT01518855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diovan
Study NCT03110341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erythropoietin
Description: rhEPO 750U/kg was injected within 72h after birth, subsequent injection was given every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections.
Study NCT03110341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
Study NCT03502486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Description: 20 minutes of cycle ergometry at 50-60% of heart rate max
Study NCT03502486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intense exercise
Description: 20 minutes of cycle ergometry at 70-80% of heart rate max
Study NCT03502486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reading
Description: 20 minutes of seated reading
Study NCT01111123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)
Description: Steroid on weekends only group
Study NCT01111123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment
Description: Placebo on weekends only group
Study NCT02259179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
Study NCT02259179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
Study NCT00844857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Fluoxetine Combination (OFC)
Description: OFC doses are capsules of 3 milligrams (mg) olanzapine and 25 mg fluoxetine (3/25), 6/25, 12/25, 6/50, or 12/50 mg to be taken orally once daily in the evening for 8 weeks.
Study NCT00844857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, once daily in the evening for 8 weeks.
Study NCT00570674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Study NCT00570674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erbitux
Study NCT00570674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00570674 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Study NCT03151980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hamam treated skin and sun exposure
Description: Hamam is a skin treatment (soaping and scrubbing).
Study NCT03151980 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Untreated skin and sun exposure
Description: Skin that will not receive Hamam.
Study NCT03160989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercises
Description: The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
Study NCT00908492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Control
Description: Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.
Study NCT00908492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental Skill Building
Description: The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
Study NCT01247207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the arm.
Study NCT02979639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Description: 2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.
Study NCT04333420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1 + BSC
Description: Phase II study part: IFX-1 + BSC
Study NCT04333420 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BSC
Description: Phase II study part: BSC
Study NCT04333420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1 + SOC
Description: Phase III study part: IFX-1 + SOC
Study NCT04333420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SOC
Description: Phase III study part: Placebo + SOC
Study NCT03523312 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated ablative IMRT (HFA-IMRT)
Description: total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions
Study NCT03523312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
Study NCT02063230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib 50mg
Description: HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1
Study NCT02063230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib 25mg
Description: Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1
Study NCT00685945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control (bradykinin)
Description: Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.
Study NCT00685945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA + bradykinin
Description: Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.
Study NCT00685945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide + L-NMMA + bradykinin
Description: Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
Study NCT01366235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chloroquine phosphate 1000 mg
Description: 1000 mg, 1day
Study NCT02578381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Pressure Wire
Description: St Jude Medical Pressure Wire
Study NCT00685945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil + L-NMMA + bradykinin
Description: Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
Study NCT02578381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Validation of Boston Scientific pressure wire
Study NCT03391609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
Study NCT03391609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine infusion
Description: Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
Study NCT01757834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWUS Elastography
Study NCT02489786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patients take 0.25 mg of digoxin daily except friday
Study NCT02489786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patients take 0.25 mg of digoxin daily except thursday and friday
Study NCT02489786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patients take 0.125 mg of digoxin daily
Study NCT02489786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: digoxin dose is calculated using Jusko-Koup method and given daily
Study NCT03340480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1402
Description: Oral
Study NCT02629874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EA-230
Description: at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.
Study NCT00799292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: 20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix
Study NCT00939484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00939484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT03122561 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol 500 mg tablet at morning
Description: Single dose oral paracetamol will be administered at 8.00 am
Study NCT03122561 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol 500 mg tablet at midday
Description: Single dose oral paracetamol will be administered at 2.00 pm
Study NCT03122561 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol 500 mg tablet at night
Description: Single dose oral paracetamol will be administered at 8.00 pm
Study NCT02859610 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: research on interactions between portal hypertension and microparticles
Study NCT02629874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
Study NCT02629874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
Study NCT02629874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01599208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TRANSCRANIAL MAGNETIC STIMULATION
Study NCT03019146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Study NCT03019146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOLD
Study NCT03019146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HUG
Study NCT00181571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate HCl (Concerta)
Description: up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.
Study NCT00181571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
Study NCT02218827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate (FML)
Description: a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
Study NCT00836082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845, FAAH inhibitor
Description: Oral solution of 0.5mg given once daily for 14 days.
Study NCT00836082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845, FAAH inhibitor
Description: Oral solution of 1mg given once daily for 14 days.
Study NCT00836082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845, FAAH inhibitor
Description: Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
Study NCT00836082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845, FAAH inhibitor
Description: A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
Study NCT00836082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845, FAAH inhibitor
Description: Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
Study NCT02578381 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Validation of Boston Scientific pressure wire
Study NCT01726725 — intervention group
Intervention type: DRUG
Intervention: desflurane
Study NCT01216176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Study NCT01216176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Study NCT01216176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anastrozole
Study NCT01216176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530 (saracatinib)
Study NCT01216176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD0530 (saracatinib)
Study NCT01216176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01807806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Role-playing game
Description: Eligible participants will be invited to engage with a role-playing game for 30 minutes. The role play presents situations where a service member/veteran interacts with family or friends.
Study NCT01410370 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 6MV-X ray
Description: 3Gy/time, 5 times/week, a total of 10 times